Expand VKTX Menu
VKTX MENU

VKTX Latest Press Releases

-- January 8, 2026 --

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity PRNewswire 7:00 AM

-- January 7, 2026 --

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer PRNewswire 7:00 AM

-- January 5, 2026 --

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference PRNewswire 4:03 PM

-- November 25, 2025 --

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference PRNewswire 4:05 PM

-- November 19, 2025 --

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 PRNewswire 2:55 AM

-- November 6, 2025 --

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek 2025 PRNewswire 7:05 AM

-- November 4, 2025 --

Viking Therapeutics to Participate at Upcoming Investor Conferences PRNewswire 4:05 PM

-- October 29, 2025 --

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek 2025 PRNewswire 4:05 PM

-- October 22, 2025 --

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PRNewswire 4:06 PM

-- October 21, 2025 --

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity PRNewswire 7:05 AM

-- October 15, 2025 --

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025 PRNewswire 4:05 PM

-- August 28, 2025 --

Viking Therapeutics to Participate at Upcoming Investor Conferences PRNewswire 4:30 PM

-- August 19, 2025 --

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity PRNewswire 7:09 AM
Market Data Delayed 15 Minutes